Navigation Links
Botulinum Toxin Share Higher in Canada Than in the US
Date:1/31/2008

Millennium Research Group's Marketrack Results find Botulinum Toxin has

Higher 2007 Market Share in Canada than in the US

WALTHAM, Mass., Jan. 31 /PRNewswire/ -- Millennium Research Group's (MRG's) Facial Aesthetic Marketrack results indicate that revenue and usage share of botulinum toxin (as a percentage of all injectables) was consistently higher in Canada than in the United States throughout 2007. With the revenue share of botulinum toxin nearly 10% higher in Canada, botulinum toxin was preferred more in Canada than it was in the US in 2007.

In Canada, dermal fillers, including hyaluronic acid (HA), collagen, and particle and polymer fillers, had a usage share approximately equal to that of botulinum toxin. In contrast, the US injectable market was dominated by dermal fillers, which represented approximately two-thirds of total facial injectables units used. Throughout 2007, the Canadian market was driven by widespread public awareness of botulinum toxin cosmetic and other advertised dermal fillers, including HA, collagen, and particle and polymer fillers. As a result, well-informed patients have been asking for injectables such as Allergan's Botox by name. Media exposure will likely not only encourage first-time patients to try Botox injections, but will also encourage existing patients to continue with their treatments.

"An increase in marketing on Allergan's behalf has had a big effect on this increase in Canada," says Jennifer Thomas, Senior Analyst at Millennium Research Group. "Media such as magazines and television shows frequently profile cosmetic procedures, which has led to increased public awareness and widespread acceptance of various less invasive aesthetic treatments."

MRG provides a number of products focused on the global facial aesthetics market. For ongoing quarterly tracking of market shares by brand, MRG offers its Marketrack service, which tracks facial aesthetic products -- such as botulinum toxin, HA, collagen, and particle and polymer injectables -- in the US and Canada. This project has been expanded to include tracking of breast implant procedures in US plastic surgery facilities. Besides market share, this service also provides brand-level usage (units, average selling price, and revenue), detailed procedure numbers, and practitioner practice information.

For in-depth analysis and five-year growth forecasts, MRG offers its Global Markets for Facial Aesthetics report series, which includes individual reports on the US, Europe, Asia Pacific, Canada, Brazil, and Mexico. Companies covered by MRG facial aesthetics market research include Allergan, Solstice Neurosciences, Ipsen, Q-Med, Medicis, Bioform Medical Inc., Dermik Labs, Sanofi-Aventis, Mentor, Teoxane, Lifecell, Fascia Biosystems, and Artes Medical.

Millennium Research Group will be attending the 66th Annual American Academy of Dermatology Meeting in San Antonio, Texas on February 2-4. Come to booth #309 to discover how we can help you meet your needs.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Environmental Toxin Collects in Breast Milk
2. UIC chemists characterize Alzheimers neurotoxin structure
3. MyoMed Launches Flash Virtual Tour of Toxin-Free Pain Relief
4. Laser Energetics Provides Joint Venture Update to Shareholders
5. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
6. Aflac Incorporated to Accelerate Share Repurchase in 2008; Authorizes Additional Share Repurchase and Increases Quarterly Cash Dividend 17.1%
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Assurant Board of Directors Declares Quarterly Dividend of $0.12 per Share
9. Moog Reports 14% Increase in Earnings Per Share
10. Rigel Announces Offering of 4,000,000 Shares of Common Stock
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... ... healthcare automation intelligence company based in New York. , “Ensuring an intuitive, user-friendly ... workflow remains unaltered. Those two fundamental reasons are the reasons this acquisition is ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... overall body strength, which often leads to a host of health issues, including ... the American Geriatrics Society discovered that good overall muscle strength in older ...
(Date:2/27/2017)... ... ... The threat of nuclear warfare has long plagued this world. In July ... testing of nuclear weapons. Years later, when her co-workers began dying, Dot started searching ... Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear testing ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines ... despite scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument that ...
(Date:2/27/2017)... ... , ... New Jersey ranks among the top five states in the entire ... for advanced services is growing. , Project WE vs C is a focused ... their non-profit partners in their fight against cancer and in support of their shared ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... Calif. , Feb. 27, 2017  Titan ... therapeutics for the treatment of select chronic diseases ... today announced that the U.S. Food & Drug ... the ropinirole implant Investigational New Drug Application (IND) ... of the clinical study pending submission of the ...
(Date:2/28/2017)... and SAN FRANCISCO , February 27, 2017 ... Se D BioMedical ... of biotechnology assets   LOI contemplates capital infusion ... for building shareholder value   Amarantus names four new appointees ... Amarantus   SeD Biomedical Inc. (SeD ...
(Date:2/28/2017)... Feb. 27, 2017 Pulmonary drug delivery market ... from USD 36.10 billion in 2016, at a CAGR ... pulmonary route as an alternate route of drug delivery, ... increasing incidence of respiratory diseases such as COPD, asthma, ... growth during the forecast period. However, emerging markets and ...
Breaking Medicine Technology: